MWT

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

Retrieved on: 
Monday, April 22, 2024
Volunteering, FDA, Safety, Pharmacokinetics, Sleep, Food, CNTA, MWT, NT2, Idiopathic hypersomnia, IND, IH, SAD, POC, Patient, Narcolepsy, NT1, OX2R, Clinical trial, PD, Investigational New Drug, KSS, Pharmaceutical industry

The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of ORX750 in healthy adult subjects.

Key Points: 
  • The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of ORX750 in healthy adult subjects.
  • The Company expects to commence dosing of the Phase 1 study in healthy volunteers imminently, and proof-of-concept data are anticipated in the second half of 2024.
  • “We are excited to begin executing what we believe is an elegant, adaptive Phase 1 study aimed at generating early proof-of-concept data for ORX750 in acutely sleep-deprived healthy volunteers in the second half of this year.
  • We expect this study to enable dose selection for planned studies evaluating ORX750 in patients with NT1 and in patient populations with normal orexin levels, including NT2 and IH.”

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Retrieved on: 
Thursday, February 8, 2024
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, MRCP, Hepatotoxicity, NT2, Neurological disorder, Narcolepsy, WCR, Fiscal, Wakefulness, Caregiver, Head, Patient, ESS, DSM-IV codes, Medicine, Neuron, OX2R, Disease, Epworth Sleepiness Scale, MWT, Pharmaceutical industry

It is currently classified into two different types: narcolepsy type 1 (NT1) caused by significant loss of orexin neurons with resulting lack of orexin, and narcolepsy type 2 (NT2) where orexin levels are generally normal.

Key Points: 
  • It is currently classified into two different types: narcolepsy type 1 (NT1) caused by significant loss of orexin neurons with resulting lack of orexin, and narcolepsy type 2 (NT2) where orexin levels are generally normal.
  • Stimulating the orexin receptor 2 in NT1 patients targets the underlying pathophysiology of the disease to restore orexin signaling.
  • Based on these results, and in consultation with global health authorities, Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 rapidly in the first half of its fiscal year 2024.
  • Results from the Phase 2b trials have no impact on the full year consolidated reported forecast for the fiscal year ending March 31, 2024 (Fiscal Year 2023).

Human medicines European public assessment report (EPAR): Wakix, pitolisant, Date of authorisation: 31/03/2016, Revision: 16, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, UNS, INN, Neuron, Fatigue, Heartburn, Woman, MWT, Sleep, ATC, Cataplexy, Insomnia, Sleep disorder, Depression, International, Tremor, Epworth Sleepiness Scale, Headache, Wakefulness, ESS, Nausea, Language, Brain, Muscle weakness, Mouth, Dizziness, Vertigo, Breakfast, Anxiety, Irritability, Observational study, European Medicines Agency, Indigestion, Tablet, Histamine, Select, Patient, Safety, Anatomy, Medicine, Somnolence, Vomiting, IIA, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Wakix, pitolisant, Date of authorisation: 31/03/2016, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Wakix, pitolisant, Date of authorisation: 31/03/2016, Revision: 16, Status: Authorised

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Retrieved on: 
Monday, October 23, 2023
DSM-IV codes, MWT, Wireless ambulatory ECG, Congress, Pathology, Dizziness, Idiopathic hypersomnia, Maintenance, Alkermes, Pharmacokinetics, Sleep, Urination, OX2R, Dysfunction, Disease, NT1, Biology, Wakefulness, Sleep onset latency, Safety, Vital signs, ALKS, Patient, Insomnia, Pharmaceutical industry, Narcolepsy

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. The ongoing phase 1 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia via once-daily, oral administration. Initial data from the single- and multiple-ascending dose evaluations in healthy volunteers and the first cohort of four patients with narcolepsy type 1 (NT1) will be presented today at the 2023 World Sleep Congress in Rio de Janeiro.

Key Points: 
  • In the four patients with NT1, treatment with ALKS 2680 demonstrated improved sleep latency compared to placebo at all doses tested, with a clear dose response.
  • The differences between ALKS 2680 and placebo were statistically significant for all doses: 1 mg (p
  • Treatment with ALKS 2680 resulted in clinically meaningful improvements in MWT from baseline at all doses tested.
  • "These initial data support our design rationale for ALKS 2680 as a highly potent, orally bioavailable, selective orexin 2 receptor agonist designed to address the underlying pathology of narcolepsy.

Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress

Retrieved on: 
Monday, October 23, 2023
DSM-IV codes, MWT, Wireless ambulatory ECG, Congress, Pathology, Dizziness, Idiopathic hypersomnia, Maintenance, Alkermes, Pharmacokinetics, Sleep, Urination, OX2R, Dysfunction, Disease, NT1, Biology, Wakefulness, Sleep onset latency, Safety, Vital signs, ALKS, Patient, Insomnia, Pharmaceutical industry, Narcolepsy

DUBLIN, Oct. 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced preliminary results, including initial proof-of-concept data, from a phase 1 study evaluating ALKS 2680, the company's novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. The ongoing phase 1 study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 in healthy volunteers and patients with narcolepsy or idiopathic hypersomnia via once-daily, oral administration. Initial data from the single- and multiple-ascending dose evaluations in healthy volunteers and the first cohort of four patients with narcolepsy type 1 (NT1) will be presented today at the 2023 World Sleep Congress in Rio de Janeiro.

Key Points: 
  • In the four patients with NT1, treatment with ALKS 2680 demonstrated improved sleep latency compared to placebo at all doses tested, with a clear dose response.
  • The differences between ALKS 2680 and placebo were statistically significant for all doses: 1 mg (p
  • Treatment with ALKS 2680 resulted in clinically meaningful improvements in MWT from baseline at all doses tested.
  • "These initial data support our design rationale for ALKS 2680 as a highly potent, orally bioavailable, selective orexin 2 receptor agonist designed to address the underlying pathology of narcolepsy.

Sunport Power Jointly Held the Launch Ceremony of Lightweight PV Module Technology Application White Paper

Retrieved on: 
Tuesday, July 4, 2023
DAS, MWT, White paper, TUV NORD, Temperature, Snow, Certification, Lightweight, Renewable energy, Albuquerque International Sunport

MUNICH, July 4, 2023 /PRNewswire/ -- On June 15, 2023, SUNPORT jointly with TUV NORD, GOODWE, DAS SOLAR and Hondol Material held the launch ceremony of Lightweight PV Module Technology Application White Paper at the Intersolar Europe exhibition.

Key Points: 
  • MUNICH, July 4, 2023 /PRNewswire/ -- On June 15, 2023, SUNPORT jointly with TUV NORD, GOODWE, DAS SOLAR and Hondol Material held the launch ceremony of Lightweight PV Module Technology Application White Paper at the Intersolar Europe exhibition.
  • With an increasing PV module market demand coming from old rooftops, curved rooftops, lightweight rooftops, outdoor activities and even moving vehicles, lightweight PV modules have a broader application scenarios.
  • Sunport Power upgraded its existent lightweight module products to increase its product reliability.
  • The "Lightweight PV Module Technology Application White Paper" is scheduled to be officially released at the end of July this year, which will help company improve the product quality and process level of lightweight modules, fill the gap in testing and certification of lightweight modules, help consumers more conveniently and quickly choose lightweight modules.

Sunport Power's Lightweight Flexible PV Module Receive TUV Certification at Intersolar Europe 2023

Retrieved on: 
Wednesday, June 28, 2023
Certification, Intersolar, TUV, Exhibition, MWT, MBC, Topcon, Welding, PV, Renewable energy, Albuquerque International Sunport

Sunport Power's upgraded reinforced lightweight flexible module made a stunning debut, won attention from professional visitors and scholars as well as the end-user market.

Key Points: 
  • Sunport Power's upgraded reinforced lightweight flexible module made a stunning debut, won attention from professional visitors and scholars as well as the end-user market.
  • And the company's full S-series lightweight flexible PV products are awarded with TUV certification at the opening day of the exhibition.
  • During the exhibition, Mr. Alexander Ohff, executive vice president of TUV issued certification for Sunport's lightweight flexible module.
  • Besides lightweight flexible series, Sunport also showcased its MWT full black PV module which already occupied a certain market share in European region.

Sunport Power Brings Its Latest Full Black Flexible PV Module Based On MBC2.0 Technology to SNEC 2023

Retrieved on: 
Friday, June 2, 2023
SNEC, Australian Academy of Science, Human, Scientia, University, MWT, Exhibition, Albuquerque International Sunport, Certification, Sunlight, MBC, CQC, TUV, News, Renewable energy, Science, PV

SHANGHAI, June 2, 2023 /PRNewswire/ -- Sunport Power Corp., Ltd., a leading photovoltaics (PV) MWT technology researcher and PV products manufacturer, has announced the unveiling of its latest solar innovation, the full black PV Modules based on MBC2.0 technology, which debuted at SNEC exhibition in Shanghai, China from 24th May to 26th May.

Key Points: 
  • SHANGHAI, June 2, 2023 /PRNewswire/ -- Sunport Power Corp., Ltd., a leading photovoltaics (PV) MWT technology researcher and PV products manufacturer, has announced the unveiling of its latest solar innovation, the full black PV Modules based on MBC2.0 technology, which debuted at SNEC exhibition in Shanghai, China from 24th May to 26th May.
  • This time, at booth W2-310, Sunport Power showcased the full MWT series products including reinforced flexible modules, full black modules, portable panels and customized flexible modules for various scenarios.
  • "We can see that Sunport Power developed different PV products for different application conditions.
  • "We will bring our new MBC2.0 product and upgraded flexible module product to InterSolar Europe in Munich from 14th to 16th June.

Sunport Power attends the Solar Solutions International 2023

Retrieved on: 
Thursday, March 30, 2023
Travel, MWT, Beauty, Solar energy, Camping, G23, Topcon, Renewable energy

AMSTERDAM, March 30, 2023 /PRNewswire/ -- Sunport Power Corp., Ltd attended the Solar Solutions International 2023 held at Expo Haarlemmermeer Amsterdam (Netherlands) from 14th to 17th March.

Key Points: 
  • AMSTERDAM, March 30, 2023 /PRNewswire/ -- Sunport Power Corp., Ltd attended the Solar Solutions International 2023 held at Expo Haarlemmermeer Amsterdam (Netherlands) from 14th to 17th March.
  • Solar Solutions International is the largest trade fair for solar energy in Northwestern Europe.
  • To stand out from hundreds of exhibitors, Sunport Power showed up several competitive products at booth G23 and attracted a lot of customers.
  • To be fit to different curved roofs and outdoor mobile charge scenarios, Sunport Power also brought its customized small dimension module and foldable solar panel.

Millimeter Wave Technology Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023
Technology, Other Manufacturing, Other Technology, Manufacturing, MWT, Radio, EHF, COVID-19, Communication, Depression, Coronavirus, MMW, Internet, Astronomy, Dermatitis, Telecommunication, Diabetes, High-pass filter, Hertz, Renewable energy, Pharmaceutical industry, Mobile phone, Powder metallurgy, Video game, Growth

The "Millimeter Wave Technology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Millimeter Wave Technology Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global millimeter wave technology market size reached US$ 1.7 Billion in 2021.
  • What are the key regions in the global millimeter wave technology market?
  • Who are the key players/companies in the global millimeter wave technology market?